FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3099464319> ?p ?o ?g. }

• W3099464319 abstract "Abstract Background CRIPTO is a multi-functional signaling protein that promotes stemness and oncogenesis. We previously developed a CRIPTO antagonist, ALK4 L75A -Fc, and showed that it causes loss of the stem cell phenotype in normal mammary epithelia suggesting it may similarly inhibit CRIPTO-dependent plasticity in breast cancer cells. Methods We focused on two triple negative breast cancer cell lines (MDA-MB-231 and MDA-MB-468) to measure the effects of ALK4 L75A -Fc on cancer cell behavior under nutrient deprivation and endoplasmic reticulum stress. We characterized the proliferation and migration of these cells in vitro using time-lapse microscopy and characterized stress-dependent changes in the levels and distribution of CRIPTO signaling mediators and cancer stem cell markers. We also assessed the effects of ALK4 L75A -Fc on proliferation, EMT, and stem cell markers in vivo as well as on tumor growth and metastasis using inducible lentiviral delivery or systemic administration of purified ALK4 L75A -Fc, which represents a candidate therapeutic approach. Results ALK4 L75A -Fc inhibited adaptive responses of breast cancer cells under conditions of nutrient and ER stress and reduced their proliferation, migration, clonogenicity, and expression of EMT and cancer stem cell markers. ALK4 L75A -Fc also inhibited proliferation of human breast cancer cells in stressed tumor microenvironments in xenografts and reduced both primary tumor size and metastatic burden. Conclusions Cancer cell adaptation to stresses such as nutrient deprivation, hypoxia, and chemotherapy can critically contribute to dormancy, metastasis, therapy resistance, and recurrence. Identifying mechanisms that govern cellular adaptation, plasticity, and the emergence of stem-like cancer cells may be key to effective anticancer therapies. Results presented here indicate that targeting CRIPTO with ALK4 L75A -Fc may have potential as such a therapy since it inhibits breast cancer cell adaptation to microenvironmental challenges and associated stem-like and EMT phenotypes." @default.
• W3099464319 created "2020-11-23" @default.
• W3099464319 creator A5001537765 @default.
• W3099464319 creator A5004363427 @default.
• W3099464319 creator A5005138004 @default.
• W3099464319 creator A5013991802 @default.
• W3099464319 creator A5018958092 @default.
• W3099464319 creator A5020642638 @default.
• W3099464319 creator A5026164041 @default.
• W3099464319 creator A5029657426 @default.
• W3099464319 creator A5038191263 @default.
• W3099464319 creator A5043311984 @default.
• W3099464319 creator A5050981241 @default.
• W3099464319 creator A5070881090 @default.
• W3099464319 creator A5071222184 @default.
• W3099464319 creator A5075271749 @default.
• W3099464319 date "2020-11-13" @default.
• W3099464319 modified "2023-10-15" @default.
• W3099464319 title "CRIPTO antagonist ALK4L75A-Fc inhibits breast cancer cell plasticity and adaptation to stress" @default.
• W3099464319 cites W1608252769 @default.
• W3099464319 cites W1977393336 @default.
• W3099464319 cites W1983931978 @default.
• W3099464319 cites W1984647773 @default.
• W3099464319 cites W1984727408 @default.
• W3099464319 cites W1989075744 @default.
• W3099464319 cites W1997500225 @default.
• W3099464319 cites W2019111347 @default.
• W3099464319 cites W2020288215 @default.
• W3099464319 cites W2023316892 @default.
• W3099464319 cites W2023427658 @default.
• W3099464319 cites W2026804255 @default.
• W3099464319 cites W2039695376 @default.
• W3099464319 cites W2044905529 @default.
• W3099464319 cites W2049273387 @default.
• W3099464319 cites W2052917322 @default.
• W3099464319 cites W2055531243 @default.
• W3099464319 cites W2055644950 @default.
• W3099464319 cites W2058642232 @default.
• W3099464319 cites W2062392648 @default.
• W3099464319 cites W2063011414 @default.
• W3099464319 cites W2063406923 @default.
• W3099464319 cites W2077320359 @default.
• W3099464319 cites W2083796374 @default.
• W3099464319 cites W2085489038 @default.
• W3099464319 cites W2086702753 @default.
• W3099464319 cites W2110212786 @default.
• W3099464319 cites W2115619508 @default.
• W3099464319 cites W2129375080 @default.
• W3099464319 cites W2140977427 @default.
• W3099464319 cites W2141458291 @default.
• W3099464319 cites W2142282255 @default.
• W3099464319 cites W2157190251 @default.
• W3099464319 cites W2159969939 @default.
• W3099464319 cites W2169111719 @default.
• W3099464319 cites W2169456326 @default.
• W3099464319 cites W2273095871 @default.
• W3099464319 cites W2508243603 @default.
• W3099464319 cites W2526348522 @default.
• W3099464319 cites W2606001457 @default.
• W3099464319 cites W2606527259 @default.
• W3099464319 cites W2762697978 @default.
• W3099464319 cites W2791143200 @default.
• W3099464319 cites W2905390578 @default.
• W3099464319 cites W2905846503 @default.
• W3099464319 cites W2913042985 @default.
• W3099464319 cites W2913227896 @default.
• W3099464319 cites W2913529616 @default.
• W3099464319 cites W2936356193 @default.
• W3099464319 cites W2936989468 @default.
• W3099464319 cites W2954031524 @default.
• W3099464319 cites W2965576600 @default.
• W3099464319 cites W3007771222 @default.
• W3099464319 doi "https://doi.org/10.1186/s13058-020-01361-z" @default.
• W3099464319 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7664111" @default.
• W3099464319 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33187540" @default.
• W3099464319 hasPublicationYear "2020" @default.
• W3099464319 type Work @default.
• W3099464319 sameAs 3099464319 @default.
• W3099464319 citedByCount "4" @default.
• W3099464319 countsByYear W30994643192021 @default.
• W3099464319 countsByYear W30994643192022 @default.
• W3099464319 crossrefType "journal-article" @default.
• W3099464319 hasAuthorship W3099464319A5001537765 @default.
• W3099464319 hasAuthorship W3099464319A5004363427 @default.
• W3099464319 hasAuthorship W3099464319A5005138004 @default.
• W3099464319 hasAuthorship W3099464319A5013991802 @default.
• W3099464319 hasAuthorship W3099464319A5018958092 @default.
• W3099464319 hasAuthorship W3099464319A5020642638 @default.
• W3099464319 hasAuthorship W3099464319A5026164041 @default.
• W3099464319 hasAuthorship W3099464319A5029657426 @default.
• W3099464319 hasAuthorship W3099464319A5038191263 @default.
• W3099464319 hasAuthorship W3099464319A5043311984 @default.
• W3099464319 hasAuthorship W3099464319A5050981241 @default.
• W3099464319 hasAuthorship W3099464319A5070881090 @default.
• W3099464319 hasAuthorship W3099464319A5071222184 @default.
• W3099464319 hasAuthorship W3099464319A5075271749 @default.
• W3099464319 hasBestOaLocation W30994643191 @default.
• W3099464319 hasConcept C121608353 @default.
• W3099464319 hasConcept C126322002 @default.
• W3099464319 hasConcept C137738243 @default.

• next